Patents by Inventor Michael Paal

Michael Paal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Agents and methods for the treatment of proliferative diseases
    Patent number: 6867198
    Abstract: The present invention provides selective kinase inhibitors of formula (I)
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: March 15, 2005
    Assignee: Eli Lilly and Company
    Inventors: Rima Salim Al-Awar, Kyle Andrew Hecker, James Edward Ray, Jianping Huang, Sajan Joseph, Tiechao Li, Michael Paal, Radhakrishnan Rathnachalam, Chuan Shih, Philip Parker Waid, Xun Zhou, Guoxin Zhu
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Patent number: 6693109
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: February 17, 2004
    Assignees: Eli Lilly and Company, Millennium Pharmaceuticals, Inc.
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Michael Paal, Gerd Ruhter, Kenneth J. Ruterbories, Robert M. Scarborough, Theo Schotten, Wolfgang Stenzel
  • Hypoglycemic imidazoline compounds
    Publication number: 20040009976
    Abstract: This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.
    Type: Application
    Filed: April 30, 2002
    Publication date: January 15, 2004
    Inventors: Kumiko Takeuchi, Michael Robert Jirousek, Michael Paal, Gerd Ruhter, Theo Schotten
  • Agents and methods for the treatment of proliferative diseases
    Publication number: 20030229026
    Abstract: The present invention provides selective kinase inhibitors of formula (I).
    Type: Application
    Filed: December 2, 2002
    Publication date: December 11, 2003
    Inventors: Rima Salim Al-Awar, Kyle Andrew Hecker, James Edward Ray, Jianping Huang, Sajan Joseph, Tiechao Li, Michael Paal, Radhakrishnan Rathnachalam, Chuan Shih, Philip Parker Waid, Xun Zhou, Guoxin Zhu
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Publication number: 20030171373
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: January 29, 2003
    Publication date: September 11, 2003
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Michael Paal, Gerd Ruhter, Kenneth J. Ruterbories, Robert M. Scarborough, Theo Schotten, Wolfgang Stenzel
  • Glycoprotein llb/llla antagonists
    Publication number: 20030130342
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: September 9, 2002
    Publication date: July 10, 2003
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, Michael John Martinelli, John Michael Morin, Michael Paal, Gerd Ruhter, Kenneth James Ruterbories, Daniel J. Sall, Theo Schotten, Marshall A. Skelton, Wolfgang Stenzel, Robert Theodore Vasileff
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Patent number: 6528534
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: March 4, 2003
    Assignees: Millennium Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Kenneth J. Ruterbories, Michael Paal, Gerd Ruhter, Theo Schotten, Wolfgang Stenzel, Robert M. Scarborough
  • Glycoprotein IIb/IIIa antagonists
    Patent number: 6448269
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: June 18, 2001
    Date of Patent: September 10, 2002
    Assignee: Eli Lilly and Company
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, Michael John Martinelli, John Michael Morin, Jr., Michael Paal, Gerd Rühter, Kenneth James Ruterbories, Daniel J. Sall, Theo Schotten, Marshall A. Skelton, Wolfgang Stenzel, Robert Theodore Vasileff
  • Hypoglycemic imidazoline compounds
    Patent number: 6410562
    Abstract: This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: June 25, 2002
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Michael Paal, Gerd Ruhter, Theo Schotten, Kumiko Takeuchi, Wolfgang Stenzel
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Publication number: 20020013325
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: July 6, 2001
    Publication date: January 31, 2002
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Kenneth J. Ruterbories, Michael Paal, Gerd Ruhter, Theo Schotten, Wolfgang Stenzel, Robert M. Scarborough
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Patent number: 6291469
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, as shown by formula (I): wherein Q, L, Ai, Bj, R0, R3, R10, m, n, p and q are as defined in the disclosure, which are useful in inhibiting of platelet aggregation.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: September 18, 2001
    Assignees: Eli Lilly and Company, COR Therapeutics Inc.
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Kenneth J. Ruterbories, Michael Paal, Gerd Ruhter, Robert M. Scarborough, Theo Schotten, Wolfgang Stenzel
  • Glycoprotein IIB IIIA antagonists
    Patent number: 6020362
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: March 24, 1998
    Date of Patent: February 1, 2000
    Assignee: Eli Lilly and Company
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, Michael John Martinelli, John Michael Morin, Jr., Michael Paal, Gerd Ruhter, Kenneth James Ruterbories, Daniel J. Sall, Theo Schotten, Marshall A. Skelton, Wolfgang Stenzel, Robert Theodore Vasileff
  • Glycoprotein IIb/IIIa antagonists
    Patent number: 5731324
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: March 24, 1998
    Assignee: Eli Lilly and Company
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, Michael John Martinelli, John Michael Morin, Jr., Michael Paal, Gerd Ruhter, Kenneth James Ruterbories, Daniel J. Sall, Theo Schotten, Marshall A. Skelton, Wolfgang Stenzel, Robert Theodore Vasileff
  • Protein kinase C inhibitors
    Patent number: 5672618
    Abstract: The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: September 30, 1997
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., John H. McDonald, III, Michael Paal, Theo Schotten, Wolfgang Stenzel
  • Pyrimidine compounds and their use as pharmaceuticals
    Patent number: 5602136
    Abstract: Compounds having the formula ##STR1## and the other variables are as defined herein, and are indicated for use in the treatment and prophylaxis of, for example, hypertension, congestive heart failure, ocular hypertension, renal failure, and CNS disorders, or are intermediates thereto.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: February 11, 1997
    Assignee: Beiersdorf-Lilly GmbH
    Inventors: Gerd R uhter, Theo Schotten, Wolfgang Stenzel, Michael Paal
  • Pyrimidine compounds and their use as pharmaceuticals
    Patent number: 5602137
    Abstract: Compounds for treating cardiovascular or circulatory disorders of the formula ##STR1## and pharmaceutically acceptable salts thereof wherein R.sup.1, R.sup.2, R.sup.3, R.sup.7, Ar.sup.1, Ar.sup.2, X, Y, and n are defined herein.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: February 11, 1997
    Assignee: Beiersdorf-Lilly GmbH
    Inventors: Gerd R uhter, Theo Schotten, Wolfgang Stenzel, Michael Paal
  • Fused pyrimidine compounds and their use as pharmaceuticals
    Patent number: 5571813
    Abstract: Pharmaceutical compounds which are azolo-fused pyrimidine compounds having the formula ##STR1## in which .dbd.
    Type: Grant
    Filed: June 6, 1994
    Date of Patent: November 5, 1996
    Assignee: Beiersdorf-Lilly GmbH
    Inventors: Gerd R uhter, Theo Schotten, Wolfgang Stenzel, Michael Paal
  • Protein kinase C inhibitors
    Patent number: 5545636
    Abstract: The present invention discloses compounds of the general formula: ##STR1## The compounds are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
    Type: Grant
    Filed: October 18, 1994
    Date of Patent: August 13, 1996
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., John H. McDonald, III, Michael Paal, Gerd R uhter, Theo Schotten, Wolfgang Stenzel
  • Cardioactive pyrrolobenzimidazoles
    Patent number: 5212186
    Abstract: Compounds for the treatment of cardiac insufficiency, an arterial thrombo embolism, an arterial occlusive disease, psoriasis, neurodermatitis, asthma, platelet aggregation and hypertension, of the formula ##STR1## in which R.sub.1 is hydrogen, C.sub.1-6 -alkyl, C.sub.2-6 -alkenyl or C.sub.3-7 -cycloalkyl,R.sub.2 is hydrogen, C.sub.1-6 -alkyl, C.sub.2-6 -alkenyl or C.sub.1-6 -hydroxyalkyl,R.sub.1 and R.sub.2 together with the carbon atom which carries them can be C.sub.3-7 -spiroalkyl,R.sub.3 is hydrogen or C.sub.1-6 -alkyl, andR.sub.4 is a cyanamido group, a 4-difluoromethoxy-3-pyridyl group or a C.sub.1-2 -nitroalkyl group, andZ is oxygen or sulphur,or a salt, acid addition salt, tautomer or optical isomer thereof.
    Type: Grant
    Filed: August 27, 1991
    Date of Patent: May 18, 1993
    Assignee: Beiersdorf Aktiengesellschaft
    Inventors: Michael Paal, Wolfgang Stenzel, Reinhard Bruckner, Ben Armah
  • Anthracycline derivatives having cytostatic activity
    Patent number: 4965352
    Abstract: The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I ##STR1## wherein R.sup.1 is a CH.sub.3 (CH.sub.2).sub.n group with n=0 to 3,R.sup.2 is a hydrogen atom or a methyl group,R.sup.3 is a hydrogen atom, a methyl group or an acyl protective group, andR.sup.4 is a hydrogen atom or an acyl protective group,and which are optionally in the form of a salt of an inorganic or organic acid, to a process for their preparation and to their use in pharmaceuticals.
    Type: Grant
    Filed: June 12, 1989
    Date of Patent: October 23, 1990
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Cenek Kolar, Michael Paal, Peter Hermentin, Hans P. Kraemer